Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil

International Journal of Impotence Research

Volumn 18, Issue 3, 2006, Pages 251-257

  Corbin, J ^a   Francis, S ^a   Zoraghi, R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allosteric cGMP binding sites; GAF; Noncatalytic cGMP binding sites; PDE inhibitors; Phosphodiesterases (PDEs); Sildenafil; Vardenafil

Indexed keywords

CYCLIC GMP; HYDROXYL GROUP; ISOBUTYLMETHYLXANTHINE; MUTANT PROTEIN; PHENYLALANINE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TYROSINE; VARDENAFIL; WATER;

ALLOSTERISM; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHEMICAL BOND; CONTROLLED STUDY; DRUG BINDING SITE; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME KINETICS; ENZYME MODIFICATION; HYDROGEN BOND; HYDROPHOBIC BOND; HYDROPHOBICITY; IC 50; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

1-METHYL-3-ISOBUTYLXANTHINE; 3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; CATALYSIS; CELL LINE; CYCLIC GMP; HUMANS; IMIDAZOLES; KINETICS; MOLECULAR STRUCTURE; MUTATION; NITROGEN; PIPERAZINES; PROTEIN BINDING; PROTEIN CONFORMATION; SUBSTRATE SPECIFICITY; SULFONES; TRIAZINES; TYROSINE;

EID: 33646578507     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901411     Document Type: Article

References (29)

1. Hamet P, Coquil JF, Bousseau-Lafortune S, Franks DJ, Tremblay J. Cyclic GMP binding and phosphodiesterase: implication for platelet function. Adv Cyclic Nucleotide Protein Phosphorylation Res 1984; 16: 119-136.
2. Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 1999; 274: 13729-13732.
3. Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 2001; 65: 1-52.
4. Corbin JD, Francis SH, Webb DJ. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology 2002; 60: 4-11.
5. Rotella DP. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 2002; 1: 674-682.
6. Montorsi F, Salonia A, Deho F, Cestari A, Guazzoni G, Rigatti P et al. Pharmacological management of erectile dysfunction. BJU Int 2003; 91: 446-454.
7. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003; 61: 8-14.
8. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342: 1802-1813.
9. Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003; 62: 121-125; discussion 125-126.
10. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397-1404.
11. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108: 2066-2069.
12. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895-900.
13. Kloner RA, Brown M, Prisant LM, Collins M. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. Am J Hypertens 2001; 14: 70-73.
14. Carson CC. Erectile dysfunction: evaluation and new treatment options. Psychosom Med 2004; 66: 664-671.
15. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impotence Res 1996; 8: 47-52.
16. Jeremy JY, Ballard SA, Naylor AM, Miller MA, Angelini GD. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 1997; 79: 958-963.
17. Saenz de Tejada I, Angulo J, Cuevas P, Fernandez A, Moncada I, Allona A et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001; 13: 282-290.
18. Sung BJ, Yeon Hwang K, Ho Jeon Y, Lee JI, Heo YS, Hwan Kim J, Moon J et al. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature 2003; 425: 98-102.
19. Turko IV, Francis SH, Corbin JD. Potential roles of conserved amino acids in the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase. J Biol Chem 1998; 273: 6460-6466.
20. Turko IV, Ballard SA, Francis SH, Corbin JD. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Mol Pharmacol 1999; 56: 124-130.
21. Francis SH, Sekhar KR, Rouse AB, Grimes KA, Corbin JD. Single step isolation of sildenafil from commercially available Viagra tablets. Int J Impot Res 2003; 15: 369-372.
22. Francis SH, Lincoln TM, Corbin JD. Characterization of a novel cGMP binding protein from rat lung. J Biol Chem 1980; 255: 620-626.
23. Wilkinson AJ, Fersht AR, Blow DM, Winter G. Site-directed mutagenesis as a probe of enzyme structure and catalysis: tyrosyl-tRNA synthetase cysteine-35 to glycine-35 mutation. Biochemistry 1983; 22: 3581-3586.
24. Andrews PR, Craik DJ, Martin JL. Functional group contributions to drug-receptor interactions. J Med Chem 1984; 27: 1648-1657.
25. Thomas MK, Francis SH, Corbin JD. Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J Biol Chem 1990; 265: 14964-14970.
26. Turko IV, Haik TL, McAllister-Lucas LM, Burns F, Francis SH, Corbin JD. Identification of key amino acids in a conserved cGMP-binding site of cGMP-binding phosphodiesterases. A putative NKXnD motif for cGMP binding. J Biol Chem 1996; 271: 22240-22244.
27. Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH et al. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol 2004; 66: 144-152.
28. Corbin JD, Beasley A, Blount MA, Francis SH. Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). Neurochem Int 2004; 45: 859-863.
29. Francis SH, Corbin JD. Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Curr Urol Rep 2003; 4: 457-465.